Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 8/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 5/20 | 0.37 |
| ▸ | CES2 | O00748 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL12497790 | 0.95 | ACE2 (0.42) | ACE2MAPTFAAHCA2MAPK1 | |
| Trifluoroacetic Acid SCHEMBL3918426 | 0.95 | ACE2 (0.53) | ACE2MAPTFAAHCES1CES2 | |
| Trifluoroacetic Acid SCHEMBL5402982 | 0.82 | ALDH1A1 (0.55) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL380951 | 0.82 | ALDH1A1 (0.53) | ACE2MAPTMEN1KMT2AHSD17B10 | |
| Trifluoroacetic Acid SCHEMBL350386 | 0.81 | BLM (0.36) | ACE2BLM | |
| Trifluoroacetic Acid SCHEMBL28259283 | 0.80 | ALDH1A1 (0.52) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL3342695 | 0.80 | CA2 (0.41) | MAPTFAAHCA2MEN1KMT2A | |
| 1-Hexanol SCHEMBL7731082 | 0.78 | LMNA (0.59) | FAAHCES1CES2MEN1CYP1A2 | |
| 1-Heptanol SCHEMBL22557209 | 0.78 | LMNA (0.59) | FAAHCES1CES2MEN1CYP1A2 | |
| Nonanol SCHEMBL271357 | 0.78 | LMNA (0.59) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115066420-A | Optically resolved Trolox intermediates and process for producing the same | 住友制药株式会社 | 2022-09-16 | — | — | CN | disclosed |
| CN-103083307-A | Fused ring compound | TAKEDA PHARMACEUTICAL | 2013-05-08 | — | — | CN | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| WO-2012118562-A1 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION, ADHD AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS EMPLOYING NOVEL BUPROPION COMPOUNDS, AND METHODS FOR PRODUCTION AND USE OF NOVEL BUPROPION COMPOUNDS AND FORMULATIONS | RHINE PHARMACEUTICALS, LLC (US) | 2012-09-07 | — | — | WO | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| US-7960582-B2 | Process for the preparation and resolution of mandelic acid derivatives | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20080312457-A1 | Process | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1818326-A1 | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds | Eisai R&D Management Co., Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| EP-1254895-B1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-6906072-B1 | Piperazine compound and pharmaceutical composition containing the compound | EISAI CO., LTD. (JP) | 2005-06-14 | — | — | US | disclosed |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI CO., LTD. | 2004-11-04 | — | — | US | disclosed |
| EP-1254895-A1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| US-6121477-A | Sulfonic ester derivatives, process for preparing the same, and use thereof | KANEKA CORPORATION (JP) | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | ACE2 532/4885MAPT 4533/4885FAAH 4513/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | ACE2 532/4885MAPT 4533/4885FAAH 4513/4885 |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1D, CACNA1B, CACNA1E | ACE2 2202/4885MAPT 1214/4885FAAH 1271/4885 |
| US-20080312457-A1 | Process | CCRL2, CCR2, C5AR2 | ACE2 208/4885MAPT 4533/4885FAAH 689/4885 |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1B, CACNA1E, CACNA1D | ACE2 2324/4885MAPT 974/4885FAAH 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.